Flexion Therapeutics, Inc. (FLXN) Lowered to “Sell” at Zacks Investment Research

Zacks Investment Research downgraded shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) from a hold rating to a sell rating in a research note released on Tuesday morning.

According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “

FLXN has been the topic of a number of other research reports. Royal Bank Of Canada reissued an outperform rating and issued a $44.00 price target on shares of Flexion Therapeutics in a research report on Thursday, August 10th. ValuEngine raised shares of Flexion Therapeutics from a sell rating to a hold rating in a research report on Friday, September 1st. Needham & Company LLC reissued a buy rating and issued a $36.00 price target on shares of Flexion Therapeutics in a research report on Sunday, September 17th. Wells Fargo & Company set a $39.00 price target on shares of Flexion Therapeutics and gave the company a buy rating in a research report on Friday, October 6th. Finally, BMO Capital Markets reissued a buy rating on shares of Flexion Therapeutics in a research report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $88.50.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.11).

ILLEGAL ACTIVITY NOTICE: “Flexion Therapeutics, Inc. (FLXN) Lowered to “Sell” at Zacks Investment Research” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/18/flexion-therapeutics-inc-flxn-lowered-to-sell-at-zacks-investment-research.html.

In related news, insider Yamo Deniz bought 3,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were acquired at an average price of $24.15 per share, with a total value of $72,450.00. Following the completion of the transaction, the insider now owns 5,000 shares of the company’s stock, valued at approximately $120,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have purchased 5,375 shares of company stock worth $131,575 in the last ninety days. 15.98% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the stock. Ardsley Advisory Partners bought a new position in Flexion Therapeutics during the second quarter worth $3,338,000. Wasatch Advisors Inc. increased its position in Flexion Therapeutics by 58.7% during the second quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock worth $20,588,000 after acquiring an additional 376,745 shares during the period. Public Employees Retirement System of Ohio increased its position in Flexion Therapeutics by 69.4% during the second quarter. Public Employees Retirement System of Ohio now owns 41,644 shares of the specialty pharmaceutical company’s stock worth $842,000 after acquiring an additional 17,066 shares during the period. Raymond James Financial Services Advisors Inc. increased its position in Flexion Therapeutics by 13.7% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 63,520 shares of the specialty pharmaceutical company’s stock worth $1,284,000 after acquiring an additional 7,667 shares during the period. Finally, The Manufacturers Life Insurance Company increased its position in Flexion Therapeutics by 3.9% during the second quarter. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company’s stock worth $441,000 after acquiring an additional 811 shares during the period. 83.26% of the stock is currently owned by institutional investors and hedge funds.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal con

According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “

FLXN has been the topic of a number of other research reports. Royal Bank Of Canada reissued an outperform rating and issued a $44.00 price target on shares of Flexion Therapeutics in a research report on Thursday, August 10th. ValuEngine raised shares of Flexion Therapeutics from a sell rating to a hold rating in a research report on Friday, September 1st. Needham & Company LLC reissued a buy rating and issued a $36.00 price target on shares of Flexion Therapeutics in a research report on Sunday, September 17th. Wells Fargo & Company set a $39.00 price target on shares of Flexion Therapeutics and gave the company a buy rating in a research report on Friday, October 6th. Finally, BMO Capital Markets reissued a buy rating on shares of Flexion Therapeutics in a research report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $88.50.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.11).

ILLEGAL ACTIVITY NOTICE: “Flexion Therapeutics, Inc. (FLXN) Lowered to “Sell” at Zacks Investment Research” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/18/flexion-therapeutics-inc-flxn-lowered-to-sell-at-zacks-investment-research.html.

In related news, insider Yamo Deniz bought 3,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were acquired at an average price of $24.15 per share, with a total value of $72,450.00. Following the completion of the transaction, the insider now owns 5,000 shares of the company’s stock, valued at approximately $120,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have purchased 5,375 shares of company stock worth $131,575 in the last ninety days. 15.98% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the stock. Ardsley Advisory Partners bought a new position in Flexion Therapeutics during the second quarter worth $3,338,000. Wasatch Advisors Inc. increased its position in Flexion Therapeutics by 58.7% during the second quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock worth $20,588,000 after acquiring an additional 376,745 shares during the period. Public Employees Retirement System of Ohio increased its position in Flexion Therapeutics by 69.4% during the second quarter. Public Employees Retirement System of Ohio now owns 41,644 shares of the specialty pharmaceutical company’s stock worth $842,000 after acquiring an additional 17,066 shares during the period. Raymond James Financial Services Advisors Inc. increased its position in Flexion Therapeutics by 13.7% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 63,520 shares of the specialty pharmaceutical company’s stock worth $1,284,000 after acquiring an additional 7,667 shares during the period. Finally, The Manufacturers Life Insurance Company increased its position in Flexion Therapeutics by 3.9% during the second quarter. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company’s stock worth $441,000 after acquiring an additional 811 shares during the period. 83.26% of the stock is currently owned by institutional investors and hedge funds.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply